ADMIRED - Ai Driven MonItoRing Equipment for Bipolar Disorder

钦佩是一个雄心勃勃的医疗保健项目，旨在通过利用数字技术、人工智能驱动的分析和主动干预来改变双相情感障碍（BD）的管理。传统的双相障碍医疗方法基于症状引发的反应，常常导致延迟治疗，危及患者的健康并影响他们的支持网络。钦佩的主要目标是开发一种集成的生物医学解决方案，彻底改变BD管理。钦佩解决方案包括以下几个部分：用于患者的电子健康数据采集系统（EHDAS）、用于持续BD管理的上下文感知移动应用程序、用于提前预测患者复发的个性化人工智能驱动服务、用于警告授权护理人员预测复发的移动应用程序、用于指导最终用户行为的协议、用于医疗决策的基于web的软件、用于人工智能服务安全边缘处理的嵌入式系统，以及用于与外部系统集成的互操作性包。通过持续监测心理和生理参数，钦佩将使用人工智能驱动的预测分析来预测个体患者的复发。当预测到复发时，将及时向患者、护理人员和临床医生发出警告，使其能够立即采取行动防止复发和随后的住院治疗。这将提高患者和家属的生活质量，同时减少与疾病相关的直接和间接费用。项目联合体由技术、研究、医学、社会科学和非政府组织实体组成，汇集了成功实施所需的多学科专门知识。将遵循模块化开发战略，在初始阶段进行实验室试验，并在项目结束时在两个不同的人群/国家展示最终原型。钦佩的目标是达到TRL 9状态，将其定位为欧盟MDR 2017/745定义下的IIa类医疗器械，将其作为平台即服务（PaaS）解决方案的一部分提供。随着对数字远程医疗解决方案的需求不断增长，该项目与当前的市场范围非常吻合，而其对边缘处理的关注进一步增强了其相关性。人们对心理健康的认识不断提高，双相障碍的患病率不断上升，这是一个有希望的市场增长机会，钦佩公司的目标是通过成为双相障碍利基市场的关键参与者来利用这一机会。总之，钦佩寻求通过采用数字技术、人工智能分析和主动干预来彻底改变BD管理，标志着从被动反应到未来基于价值的P4（预测性、预防性、个性化和参与性）医学的转变。通过创新和全面的方法解决双相障碍的挑战，钦佩有可能显著改善全球数百万受这种精神疾病影响的人的生活。

ADMIRED is an ambitious healthcare project seeking to transform the management of Bipolar Disorder (BD) by harnessing digital technologies, AI-driven analytics, and proactive interventions. The traditional healthcare approach for BD, based on symptom-triggered responses, often leads to delayed treatment, jeopardizing patients' health and impacting their support network. ADMIRED's main objective is to develop an integrated biomedical solution that revolutionizes BD management.The ADMIRED solution comprises several components: an Electronic Health Data Acquisition System (EHDAS) for patients, a context-aware mobile application for continuous BD management, individualized AI-driven services to predict patient relapses in advance, a mobile app to warn authorized caregivers about predicted relapses, protocols to guide end-user behaviours, web-based software for medical decision-making, an embedded system for secure edge processing of AI services, and an interoperability package for integration with external systems.Through continuous monitoring of psychological and physiological parameters, ADMIRED will use AI-driven predictive analytics to anticipate individual patient relapses. When relapse is predicted, timely warnings will be sent to patients, caregivers, and clinicians, enabling immediate actions to prevent relapses and subsequent hospitalizations. This will enhance the quality of life for patients and families while reducing direct and indirect costs associated with the disease.The project consortium consists of technical, research, medical, social science, and NGO entities, bringing together the necessary multidisciplinary expertise for successful implementation. A modular development strategy will be followed, with a lab pilot in the initial phase and a final prototype demonstrated in two distinct populations/countries by the project's conclusion.ADMIRED aims to reach TRL 9 status, positioning it as a Class IIa medical device under the EU MDR 2017/745 definition, offering it as part of a Platform-as-a-Service (PaaS) solution. With the growing demand for digital telemedicine solutions, the project aligns well with the current market scope, while its focus on edge processing further enhances its relevance. The increasing awareness of mental health and the rising prevalence of BD contribute to a promising market growth opportunity, which ADMIRED aims to capitalize on by becoming a key player in the BD niche market. In conclusion, ADMIRED seeks to revolutionize BD management by embracing digital technologies, AI analytics, and proactive interventions, marking a shift from reactive to future value-based P4 (Predictive, Preventive, Personalized, and Participatory) medicine. By addressing the challenges of BD with an innovative and comprehensive approach, ADMIRED has the potential to significantly improve the lives of millions of individuals worldwide affected by this mental illness.